Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

IL0006290147
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG000HD3FM1
TEVA
Teva Pharmaceutical Industries Ltd
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: High-Tech-Biomed-Pharma · THEMEFOLIO: $HLTH
NAME
Teva Pharmaceutical Industries Ltd
ISIN
IL0006290147
TICKER
TEVA
MIC
XTAE
REUTERS
TEVA.TA
BLOOMBERG
TEVA IT
Wed, 05.11.2025       Teva
IL0006290147

For an accessible version of this Press Release, please visit www.tevapharm.com...
Read more
Teva
Technical Analysis Termsheets Terminal
Permalink
Fri, 31.10.2025       Teva
IL0006290147

TEL AVIV, Israel, Oct. 31, 2025 (GLOBE NEWSWIRE) --  Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at two upcoming investor conferences in November as follows:...
Read more
Teva
Technical Analysis Termsheets Terminal
Permalink
Tue, 21.10.2025       Teva
IL0006290147

TEL AVIV, Israël, 21 oct. 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, une filiale de Teva Pharmaceutical Industries Ltd. (NYSE et TASE : TEVA), a conclu un accord de licence avec Prestige Biopharma, pour la commercialisation de Tuznue® (trastuzumab), un biosimilaire d’Herceptin®, sur la plupart des marchés européens....
Read more
Teva
Technical Analysis Termsheets Terminal
Permalink
Mon, 20.10.2025       Teva
IL0006290147

TEL AVIV, Israel, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) entered into a license agreement with Prestige Biopharma, for the commercialization of Tuznue® (trastuzumab), a biosimilar to Herceptin®, across a majority of European markets....
Read more
Teva
Technical Analysis Termsheets Terminal
Permalink
Fri, 10.10.2025       Teva
IL0006290147

PARSIPPANY, N.J. and TEL AVIV, Israel and PARIS, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell (Euronext: MEDCL), announced today that the U.S. Food and Drug Administration (FDA) has approved UZEDY® (risperidone) as a once-monthly extended-relea...
Read more
Teva
Technical Analysis Termsheets Terminal
Permalink
Thu, 25.09.2025       Teva
IL0006290147

TEL AVIV, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its third quarter 2025 financial results on Wednesday, November 5, 2025, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day,...
Read more
Teva
Technical Analysis Termsheets Terminal
Permalink
Thu, 25.09.2025       Teva
IL0006290147

TEL AVIV, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q3 2025 Aide Memoire is available on the “Investors” page on its website....
Read more
Teva
Technical Analysis Termsheets Terminal
Permalink
Sun, 21.09.2025       Teva
IL0006290147

PARSIPPANY, N.J. and TEL AVIV, Israel, Sept. 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of data from a real-world survey of patients taking AUSTEDO XR® (deutetrabenazine) extended-release tablets. Patients taking AUSTEDO XR rep...
Read more
Teva
Technical Analysis Termsheets Terminal
Permalink
Sun, 21.09.2025       Teva
IL0006290147

PARSIPPANY, N.J., and TEL AVIV, Israel, Sept. 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of 10 posters from its innovative schizophrenia medicines portfolio, including long-term safety data from the completed SOLARIS Phase 3 tri...
Read more
Teva
Technical Analysis Termsheets Terminal
Permalink
Tue, 16.09.2025       Teva
IL0006290147

TEL AVIV, Israel, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced plans to present data from the completed phase 3 SOLARIS trial at the 2025 Psych Congress Annual Meeting, taking place from September 17 – 21, 2025, in San Diego, California....
Read more
Teva
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Tue, 02.09.2025       Teva
IL0006290147

TEL AVIV, Israel, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at two upcoming investor conferences in September as follows:...
Read more
Teva
Technical Analysis Termsheets Terminal
Permalink
Thu, 28.08.2025       Teva
IL0006290147

Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss...
Read more
Teva
Technical Analysis Termsheets Terminal
Permalink
Wed, 30.07.2025       Teva
IL0006290147

Q2 2025 Highlights:...
Read more
Teva
Technical Analysis Termsheets Terminal
Permalink
Thu, 26.06.2025       Teva
IL0006290147

TEL AVIV, Israel, June 26, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q2 2025 Aide Memoire is available on the “Investors” page on its website....
Read more
Teva
Technical Analysis Termsheets Terminal
Permalink
Tue, 24.06.2025       Teva
IL0006290147

TEL AVIV, Israel, June 24, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) gab heute bekannt, dass die abschließende Analyse der paneuropäischen Phase-IV-PEARL-Studie für die Prävention von Migräne zeige, dass AJOVY (fremanezumab), ein monoklonaler CGRP (Anti-Calcitonin Gene-Related Peptide)-Antikörper, über ein...
Read more
Teva
Technical Analysis Termsheets Terminal
Permalink
Mon, 23.06.2025       Teva
IL0006290147

TEL AVIV, Israel, June 23, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the final analysis of the pan-European PEARL Phase 4 migraine prevention study showed that AJOVY (fremanezumab), an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody, delivered sustained effectiveness ov...
Read more
Teva
Technical Analysis Termsheets Terminal
Permalink
Tue, 03.06.2025       Teva
IL0006290147

TEL AVIV, Israel, June 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today the pricing and early acceptance results of its previously announced tender offers (the “Offers”) to purchase for cash the outstanding notes issued by finance subsidiaries of Teva and guaranteed by Teva of the ser...
Read more
Teva
Technical Analysis Termsheets Terminal
Permalink
Tue, 03.06.2025       Teva
IL0006290147

TEL AVIV, Israel, June 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today the early tender results in connection with its previously announced tender offers (the “Offers”) as specified below for the following series of notes issued by finance subsidiaries of Teva and guaranteed by Teva:...
Read more
Teva
Technical Analysis Termsheets Terminal
Permalink
Sat, 31.05.2025       Teva
IL0006290147

PARSIPPANY, N.J. and TEL AVIV, Israel, May 30, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced results from a study of treatment patterns among patients with tardive dyskinesia (TD) residing in long-term care (LTC) facilities, highlighting a critical gap...
Read more
Teva
Technical Analysis Termsheets Terminal
Permalink
Sat, 31.05.2025       Teva
IL0006290147

PARSIPPANY, N.J. and TEL AVIV, Israel, May 30, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of real-world clinical outcomes, treatment patterns and healthcare resource utilization (HCRU) data evaluating UZEDY® (risperidone), an extend...
Read more
Teva
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Thu, 29.05.2025       Teva
IL0006290147

TEL AVIV, Israel and PARSIPPANY, N.J., May 29, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), is hosting today a 2025 Innovation & Strategy Day, to launch the acceleration phase of its “Pivot to Growth” strategy and to discuss portfolio priorities as it evolves into a global biopharmaceutical leader. The e...
Read more
Teva
Technical Analysis Termsheets Terminal
Permalink
Tue, 27.05.2025       Teva
IL0006290147

Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA...
Read more
Teva
Technical Analysis Termsheets Terminal
Permalink
Thu, 22.05.2025       Teva
IL0006290147

TEL AVIV, Israel, May 22, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today that it is increasing the maximum tender amount of its tender offer previously announced on May 19, 2025 from $2.0 billion (equivalent) aggregate cash purchase price (exclusive of accrued and unpaid interest) to ap...
Read more
Teva
Technical Analysis Termsheets Terminal
Permalink
Tue, 20.05.2025       Teva
IL0006290147

TEL AVIV, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today that it successfully upsized its offering and priced approximately $2,300,000,000 (equivalent) of its senior notes (the “Notes”). The principal amount of the offering was increased from the previously announced off...
Read more
Teva
Technical Analysis Termsheets Terminal
Permalink
Mon, 19.05.2025       Teva
IL0006290147

TEL AVIV, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today its intention to issue $2,000,000,000 (equivalent) of senior notes through its special purpose finance subsidiaries. Teva Pharmaceutical Finance Netherlands II B.V. (“Teva Finance II”) intends to offer EUR-denomina...
Read more
Teva
Technical Analysis Termsheets Terminal
Permalink
Mon, 19.05.2025       Teva
IL0006290147

TEL AVIV, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today that it has commenced tender offers (the “Offers”) to purchase for cash for a combined aggregate purchase price (exclusive of accrued and unpaid interest) of up to $2,000,000,000 (equivalent) (the “Total Maximum Am...
Read more
Teva
Technical Analysis Termsheets Terminal
Permalink
Thu, 15.05.2025       Teva
IL0006290147

Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy...
Read more
Teva
Technical Analysis Termsheets Terminal
Permalink
Wed, 07.05.2025       Teva
IL0006290147

For an accessible version of this Press Release, please visit www.tevapharm.com...
Read more
Teva
Technical Analysis Termsheets Terminal
Permalink
Mon, 31.03.2025       Teva
IL0006290147

PARSIPPANY, N.J. and TEL AVIV, Israel, March 31, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of a patient and healthcare professional (HCP) attitudes and experiences survey study, complementing the successful Phase 3 Subcutaneous Ola...
Read more
Teva
Technical Analysis Termsheets Terminal
Permalink
Thu, 27.03.2025       Teva
IL0006290147

TEL AVIV, Israel, March 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q1 2025 Aide Memoire is available on the “Investors” page on its website....
Read more
Teva
Technical Analysis Termsheets Terminal
Permalink
Thu, 27.02.2025       Teva
IL0006290147

The $2 million in new funding is part of a $4 million commitment from Teva, launched in 2022, to expand access to critical mental health services across 10 states The $2 million in new funding is part of a $4 million commitment from Teva, launched in 2022, to expand access to critical mental health services across 10 states...
Read more
Teva
Technical Analysis Termsheets Terminal
Permalink
Sat, 22.02.2025       Teva
IL0006290147

Teva hosting investor call Monday, February 24 at 8:00 a.m. U.S. ET Teva hosting investor call Monday, February 24 at 8:00 a.m. U.S. ET...
Read more
Teva
Technical Analysis Termsheets Terminal
Permalink
Fri, 21.02.2025       Teva
IL0006290147

AMSTERDAM, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Laut einer neuen Studie von Teva Pharmaceuticals Europe werden 46 % der Generika auf der EU-Liste der kritischen Arzneimittel von nur einem Anbieter bereitgestellt. Wenn man Anbieter mit einem Marktanteil von über 60 % betrachtet, verdoppelt sich diese Zahl auf 83 %. Die Studie Generic Health Check Eur...
Read more
Teva
Technical Analysis Termsheets Terminal
Permalink
Fri, 21.02.2025       Teva
IL0006290147

PARSIPPANY, N.J. and REYKJAVÍK, Iceland, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Alvotech (NASDAQ: ALVO) today announced the availability of SELARSDI™ (ustekinumab-aekn) injection in the U.S., a biosimilar to Stelara® (ustekinumab), for the tre...
Read more
Teva
Technical Analysis Termsheets Terminal
Permalink